Annals of the Rheumatic Diseases最新文献

筛选
英文 中文
New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens. 世卫组织新的 ACPA 标准实现了抗CCP2 检测方法的标准化,但未能实现使用不同抗原的其他 ACPA 检测方法的标准化。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-226169
Lieve Van Hoovels, Liesbeth E Bakker-Jonges, Dina Vara, Caroline Bijnens, Lucy Studholme, Daniela Sieghart, Bert Vander Cruyssen, Patrick Verschueren, Guenter Steiner, Jan G M C Damoiseaux, Xavier Bossuyt
{"title":"New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens.","authors":"Lieve Van Hoovels, Liesbeth E Bakker-Jonges, Dina Vara, Caroline Bijnens, Lucy Studholme, Daniela Sieghart, Bert Vander Cruyssen, Patrick Verschueren, Guenter Steiner, Jan G M C Damoiseaux, Xavier Bossuyt","doi":"10.1136/ard-2024-226169","DOIUrl":"10.1136/ard-2024-226169","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1793-1794"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. 接受比美单抗治疗的轴性脊柱关节炎患者葡萄膜炎发生率较低:2b/3期试验的汇总结果。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-225933
Matthew A Brown, Martin Rudwaleit, Floris A van Gaalen, Nigil Haroon, Lianne S Gensler, Carmen Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, Thomas Vaux, Katy White, Atul Deodhar, Irene van der Horst-Bruinsma
{"title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials.","authors":"Matthew A Brown, Martin Rudwaleit, Floris A van Gaalen, Nigil Haroon, Lianne S Gensler, Carmen Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, Thomas Vaux, Katy White, Atul Deodhar, Irene van der Horst-Bruinsma","doi":"10.1136/ard-2024-225933","DOIUrl":"10.1136/ard-2024-225933","url":null,"abstract":"<p><strong>Objectives: </strong>Acute anterior uveitis ('uveitis') is a common axial spondyloarthritis (axSpA) extramusculoskeletal manifestation. Interleukin (IL)-17 is implicated in its pathogenesis, however, there is conflicting evidence for IL-17A inhibition in uveitis management. We report pooled analyses of uveitis incidence in patients receiving bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, from phase 2b/3 trials.</p><p><strong>Methods: </strong>Data were pooled for patients receiving BKZ 160 mg or placebo in the double-blind treatment period of the phase 3 BE MOBILE 1 (NCT03928704; non-radiographic axSpA) and BE MOBILE 2 (NCT03928743; radiographic axSpA) trials. Data were separately pooled for patients treated with at least one BKZ dose in the BE MOBILE trials and their ongoing open-label extension (OLE; NCT04436640), and the phase 2b BE AGILE trial (NCT02963506; radiographic axSpA) and its ongoing OLE (NCT03355573). Uveitis rates and exposure-adjusted incidence rates (EAIR)/100 patient-years (PYs) are reported.</p><p><strong>Results: </strong>In the BE MOBILE 1 and 2 double-blind treatment period, 0.6% (2/349) of patients receiving BKZ experienced uveitis vs 4.6% (11/237) receiving placebo (nominal p=0.001; EAIR (95% CI): 1.8/100 PYs (0.2 to 6.7) vs 15.4/100 PYs (95% CI 7.7 to 27.5)). In patients with history of uveitis, EAIR was lower in patients receiving BKZ (6.2/100 PYs (95% CI 0.2 to 34.8); 1.9%) vs placebo (70.4/100 PYs (95% CI 32.2 to 133.7); 20.0%; nominal p=0.004). In the phase 2b/3 pool (N=848; BKZ exposure: 2034.4 PYs), EAIR remained low (1.2/100 PYs (95% CI 0.8 to 1.8)).</p><p><strong>Conclusions: </strong>Bimekizumab, a dual-IL-17A/F inhibitor, may confer protective effects for uveitis in patients with axSpA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1722-1730"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development. Th9 中的正反馈环 PU.1-IL9 促进类风湿性关节炎的发展。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-226067
Jiajie Tu, Weile Chen, Wei Huang, Xinming Wang, Yilong Fang, Xuming Wu, Huiru Zhang, Chong Liu, Xuewen Tan, Xiangling Zhu, Huihui Wang, Dafei Han, Yizhao Chen, Anqi Wang, Yuanyuan Zhou, Zimeng Xue, Hui Xue, Shangxue Yan, Lingling Zhang, Zhenbao Li, Chunlan Yang, Yujie Deng, Shihao Zhang, Chen Zhu, Wei Wei
{"title":"Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.","authors":"Jiajie Tu, Weile Chen, Wei Huang, Xinming Wang, Yilong Fang, Xuming Wu, Huiru Zhang, Chong Liu, Xuewen Tan, Xiangling Zhu, Huihui Wang, Dafei Han, Yizhao Chen, Anqi Wang, Yuanyuan Zhou, Zimeng Xue, Hui Xue, Shangxue Yan, Lingling Zhang, Zhenbao Li, Chunlan Yang, Yujie Deng, Shihao Zhang, Chen Zhu, Wei Wei","doi":"10.1136/ard-2024-226067","DOIUrl":"10.1136/ard-2024-226067","url":null,"abstract":"<p><strong>Objectives: </strong>T helper 9 (Th9) cells are recognised for their characteristic expression of the transcription factor PU.1 and production of interleukin-9 (IL-9), which has been implicated in various autoimmune diseases. However, its precise relationship with rheumatoid arthritis (RA) pathogenesis needs to be further clarified.</p><p><strong>Methods: </strong>The expression levels of PU.1 and IL-9 in patients with RA were determined by ELISA, western blotting (WB) and immunohistochemical staining. PU.1-T cell-conditional knockout (KO) mice, IL-9 KO and IL-9R KO mice were used to establish collagen antibody-induced arthritis (CAIA), respectively. The inhibitor of PU.1 and IL-9 blocking antibody was used in collagen-induced arthritis (CIA). In an in vitro study, the effects of IL-9 were investigated using siRNAs and IL-9 recombinant proteins. Finally, the underlying mechanisms were further investigated by luciferase reporter analysis, WB and Chip-qPCR.</p><p><strong>Results: </strong>The upregulation of IL-9 expression in patients with RA exhibited a positive correlation with clinical markers. Using CAIA and CIA model, we demonstrated that interventions targeting PU.1 and IL-9 substantially mitigated the inflammatory phenotype. Furthermore, in vitro assays provided the proinflammatory role of IL-9, particularly in the hyperactivation of macrophages and fibroblast-like synoviocytes. Mechanistically, we uncovered that PU.1 and IL-9 form a positive feedback loop in RA: (1) PU.1 directly binds to the IL-9 promoter, activating its transcription and (2) Th9-derived IL-9 induces PU.1 via the IL-9R-JAK1/STAT3 pathway.</p><p><strong>Conclusions: </strong>These results support that the PU.1-IL-9 axis forms a positive loop in Th9 dysregulation of RA. Targeting this signalling axis presents a potential target approach for treating RA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1707-1721"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of international consensus on a standardised image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI: an ASAS-SPARTAN collaboration. 就磁共振成像诊断评估骶髂关节的标准化图像采集协议达成国际共识:ASAS-SPARTAN 合作。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-225882
Robert G W Lambert, Xenofon Baraliakos, Stephanie A Bernard, John A Carrino, Torsten Diekhoff, Iris Eshed, Kay Geert A Hermann, Nele Herregods, Jacob Jaremko, Lennart Bo Jans, Anne Grethe Jurik, John M D O'Neill, Monique Reijnierse, Michael J Tuite, Walter P Maksymowych
{"title":"Development of international consensus on a standardised image acquisition protocol for diagnostic evaluation of the sacroiliac joints by MRI: an ASAS-SPARTAN collaboration.","authors":"Robert G W Lambert, Xenofon Baraliakos, Stephanie A Bernard, John A Carrino, Torsten Diekhoff, Iris Eshed, Kay Geert A Hermann, Nele Herregods, Jacob Jaremko, Lennart Bo Jans, Anne Grethe Jurik, John M D O'Neill, Monique Reijnierse, Michael J Tuite, Walter P Maksymowych","doi":"10.1136/ard-2024-225882","DOIUrl":"10.1136/ard-2024-225882","url":null,"abstract":"<p><strong>Background: </strong>A range of sacroiliac joint (SIJ) MRI protocols are used in clinical practice but not all were specifically designed for diagnostic ascertainment. This can be confusing and no standard diagnostic SIJ MRI protocol is currently accepted worldwide.</p><p><strong>Objective: </strong>To develop a standardised MRI image acquisition protocol (IAP) for diagnostic ascertainment of sacroiliitis.</p><p><strong>Methods: </strong>13 radiologist members of Assessment of SpondyloArthritis International Society (ASAS) and the SpondyloArthritis Research and Treatment Network (SPARTAN) plus two rheumatologists participated in a consensus exercise. A draft IAP was circulated with background information and online examples. Feedback on all issues was tabulated and recirculated. The remaining points of contention were resolved and the revised IAP was presented to the entire ASAS membership.</p><p><strong>Results: </strong>A minimum four-sequence IAP is recommended for diagnostic ascertainment of sacroiliitis and its differential diagnoses meeting the following requirements. Three semicoronal sequences, parallel to the dorsal cortex of the S2 vertebral body, should include sequences sensitive for detection of (1) changes in fat signal and structural damage with T1-weighting; (2) active inflammation, being T2-weighted with fat suppression; (3) bone erosion optimally depicting the bone-cartilage interface of the articular surface and (4) a semiaxial sequence sensitive for detection of inflammation. The IAP was approved at the 2022 ASAS annual meeting with 91% of the membership in favour.</p><p><strong>Conclusion: </strong>A standardised IAP for SIJ MRI for diagnostic ascertainment of sacroiliitis is recommended and should be composed of at least four sequences that include imaging in two planes and optimally visualise inflammation, structural damage and the bone-cartilage interface.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1628-1635"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS). 疑似或已知轴性脊柱关节炎影像学转诊的临床信息:国际脊柱关节炎评估协会(ASAS)的建议。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-226280
Torsten Diekhoff, Chiara Giraudo, Pedro M Machado, Michael Mallinson, Iris Eshed, Hildrun Haibel, Kay Geert Hermann, Manouk de Hooge, Lennart Jans, Anne Grethe Jurik, Robert Gw Lambert, Walter Maksymowych, Helena Marzo-Ortega, Victoria Navarro-Compán, Mikkel Østergaard, Susanne Juhl Pedersen, Monique Reijnierse, Martin Rudwaleit, Fernando A Sommerfleck, Ulrich Weber, Xenofon Baraliakos, Denis Poddubnyy
{"title":"Clinical information on imaging referrals for suspected or known axial spondyloarthritis: recommendations from the Assessment of Spondyloarthritis International Society (ASAS).","authors":"Torsten Diekhoff, Chiara Giraudo, Pedro M Machado, Michael Mallinson, Iris Eshed, Hildrun Haibel, Kay Geert Hermann, Manouk de Hooge, Lennart Jans, Anne Grethe Jurik, Robert Gw Lambert, Walter Maksymowych, Helena Marzo-Ortega, Victoria Navarro-Compán, Mikkel Østergaard, Susanne Juhl Pedersen, Monique Reijnierse, Martin Rudwaleit, Fernando A Sommerfleck, Ulrich Weber, Xenofon Baraliakos, Denis Poddubnyy","doi":"10.1136/ard-2024-226280","DOIUrl":"10.1136/ard-2024-226280","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to establish expert consensus recommendations for clinical information on imaging requests in suspected/known axial spondyloarthritis (axSpA), focusing on enhancing diagnostic clarity and patient care through guidelines.</p><p><strong>Materials and methods: </strong>A specialised task force was formed, comprising 7 radiologists, 11 rheumatologists from the Assessment of Spondyloarthritis International Society (ASAS) and a patient representative. Using the Delphi method, two rounds of surveys were conducted among ASAS members. These surveys aimed to identify critical elements for imaging referrals and to refine these elements for practical application. The task force deliberated on the survey outcomes and proposed a set of recommendations, which were then presented to the ASAS community for a decisive vote.</p><p><strong>Results: </strong>The collaborative effort resulted in a set of six detailed recommendations for clinicians involved in requesting imaging for patients with suspected or known axSpA. These recommendations cover crucial areas, including clinical features indicative of axSpA, clinical features, mechanical factors, past imaging data, potential contraindications for specific imaging modalities or contrast media and detailed reasons for the examination, including differential diagnoses. Garnering support from 73% of voting ASAS members, these recommendations represent a consensus on optimising imaging request protocols in axSpA.</p><p><strong>Conclusion: </strong>The ASAS recommendations offer comprehensive guidance for rheumatologists in requesting imaging for axSpA, aiming to standardise requesting practices. By improving the precision and relevance of imaging requests, these guidelines should enhance the clinical impact of radiology reports, facilitate accurate diagnosis and consequently improve the management of patients with axSpA.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1636-1643"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: AB0159 Health related quality of life among patients with rheumatoid arthritis at Tikur Anbessa specialized Hospital. A Hospital- based cross sectional study.
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/annrheumdis-2022-eular.451corr1
{"title":"Correction: AB0159 Health related quality of life among patients with rheumatoid arthritis at Tikur Anbessa specialized Hospital. A Hospital- based cross sectional study.","authors":"","doi":"10.1136/annrheumdis-2022-eular.451corr1","DOIUrl":"https://doi.org/10.1136/annrheumdis-2022-eular.451corr1","url":null,"abstract":"","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":"83 12","pages":"e28"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study. 类风湿性关节炎患者体内存在具有自身免疫诱导潜能的异常肠道噬菌体:一项配对同胞研究。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-225564
Fanlei Hu, Xin Li, Kai Liu, Yanpeng Li, Yang Xie, Chaonan Wei, Shuyan Liu, Jing Song, Ping Wang, Lianjie Shi, Chun Li, Jing Li, Liling Xu, Jimeng Xue, Xi Zheng, Mingxin Bai, Xiangyu Fang, Xu Jin, Lulu Cao, Pei Hao, Jing He, Jun Wang, Chiyu Zhang, Zhanguo Li
{"title":"Rheumatoid arthritis patients harbour aberrant enteric bacteriophages with autoimmunity-provoking potential: a paired sibling study.","authors":"Fanlei Hu, Xin Li, Kai Liu, Yanpeng Li, Yang Xie, Chaonan Wei, Shuyan Liu, Jing Song, Ping Wang, Lianjie Shi, Chun Li, Jing Li, Liling Xu, Jimeng Xue, Xi Zheng, Mingxin Bai, Xiangyu Fang, Xu Jin, Lulu Cao, Pei Hao, Jing He, Jun Wang, Chiyu Zhang, Zhanguo Li","doi":"10.1136/ard-2024-225564","DOIUrl":"10.1136/ard-2024-225564","url":null,"abstract":"<p><strong>Objectives: </strong>Viruses have been considered as important participants in the development of rheumatoid arthritis (RA). However, the profile of enteric virome and its role in RA remains elusive. This study aimed to investigate the atlas and involvement of virome in RA pathogenesis.</p><p><strong>Methods: </strong>Faecal samples from 30 pairs of RA and healthy siblings that minimise genetic interferences were collected for metagenomic sequencing. The α and β diversity of the virome and the virome-bacteriome interaction were analysed. The differential bacteriophages were identified, and their correlations with clinical and immunological features of RA were analysed. The potential involvement of these differential bacteriophages in RA pathogenesis was further investigated by auxiliary metabolic gene annotation and molecular mimicry study. The responses of CD4<sup>+</sup> T cells and B cells to the mimotopes derived from the differential bacteriophages were systemically studied.</p><p><strong>Results: </strong>The composition of the enteric bacteriophageome was distorted in RA. The differentially presented bacteriophages correlated with the immunological features of RA, including anti-CCP autoantibody and HLA-DR shared epitope. Intriguingly, the glycerolipid and purine metabolic genes were highly active in the bacteriophages from RA. Moreover, peptides of RA-enriched phages, in particular <i>Prevotella</i> phage and <i>Oscillibacter</i> phage could provoke the autoimmune responses in CD4<sup>+</sup> T cells and plasma cells via molecular mimicry of the disease-associated autoantigen epitopes, especially those of Bip.</p><p><strong>Conclusions: </strong>This study provides new insights into enteric bacteriophageome in RA development. In particular, the aberrant bacteriophages demonstrated autoimmunity-provoking potential that would promote the occurrence of the disease.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1677-1690"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141858891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial. 类风湿因子、抗瓜氨酸蛋白抗体和共同表位与早期类风湿关节炎患者对初始治疗的临床反应的关系:一项随机对照试验的数据。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-226024
Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C Nordström, Michael T Nurmohamed, Anna Rudin, Mikkel Østergaard, Espen A Haavardsholm, Kim Hørslev-Petersen, Till Uhlig, Tuulikki Sokka-Isler, Bjorn Gudbjornsson, Gerdur Grondal, Giulia Frazzei, Jeroen Christiaans, Gertjan Wolbink, Theo Rispens, Jos W R Twisk, Ronald F van Vollenhoven
{"title":"Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.","authors":"Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C Nordström, Michael T Nurmohamed, Anna Rudin, Mikkel Østergaard, Espen A Haavardsholm, Kim Hørslev-Petersen, Till Uhlig, Tuulikki Sokka-Isler, Bjorn Gudbjornsson, Gerdur Grondal, Giulia Frazzei, Jeroen Christiaans, Gertjan Wolbink, Theo Rispens, Jos W R Twisk, Ronald F van Vollenhoven","doi":"10.1136/ard-2024-226024","DOIUrl":"10.1136/ard-2024-226024","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active conventional treatment (ACT).</p><p><strong>Methods: </strong>Patients with treatment-naïve early rheumatoid arthritis were randomised in the NORD-STAR trial to ACT, certolizumab pegol, abatacept or tocilizumab, all with methotrexate. Centralised laboratory analyses for ACPA, RF and SE were performed. Clinical Disease Activity Index remission was analysed longitudinally with logistic generalised estimating equations. Differences in treatment effect across RF, ACPA and SE subgroups were assessed with interaction terms at 24 and 48 weeks, adjusted for sex, country, age, body mass index, Disease Activity Score of 28 joints based on C-reactive protein and smoking.</p><p><strong>Results: </strong>In total, 778 patients were included. At 24 weeks, abatacept treatment showed a better response than ACT in the RF and/or ACPA-positive subgroups, but this effect was not significantly different from the negative subgroups. By 48 weeks, abatacept treatment showed better response regardless of RF/ACPA status. No differences were found across RF, ACPA, SE allele, valine at amino acid position 11 or valine-arginine-alanine haplotype subgroups for any biological treatment at 48 weeks.</p><p><strong>Conclusions: </strong>Based on this randomised controlled trial, abatacept treatment was associated with a better response than ACT in the RF and/or ACPA-positive subgroup at 24 weeks, but this was no longer seen at 48 weeks; adding SE allele-related genetic markers did not strengthen the association. Moreover, ACPA, RF and SE allele-related genotypes were not, alone or in combination, associated with clinical responses of importance sufficiently strongly to warrant implementation in clinical practice.</p><p><strong>Trial registration number: </strong>EudraCT 2011-004720-35; ClinicalTrials.gov NCT01491815.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1657-1665"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141854585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases. 75 年糖皮质激素发现之旅:我们对风湿性疾病中糖皮质激素受体机制认识的演变。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2023-225371
Ann-Kathrin Eiers, Sabine Vettorazzi, Jan P Tuckermann
{"title":"Journey through discovery of 75 years glucocorticoids: evolution of our knowledge of glucocorticoid receptor mechanisms in rheumatic diseases.","authors":"Ann-Kathrin Eiers, Sabine Vettorazzi, Jan P Tuckermann","doi":"10.1136/ard-2023-225371","DOIUrl":"10.1136/ard-2023-225371","url":null,"abstract":"<p><p>For three-quarters of a century, glucocorticoids (GCs) have been used to treat rheumatic and autoimmune diseases. Over these 75 years, our understanding of GCs binding to nuclear receptors, mainly the glucocorticoid receptor (GR) and their molecular mechanisms has changed dramatically. Initially, in the late 1950s, GCs were considered important regulators of energy metabolism. By the 1970s/1980s, they were characterised as ligands for hormone-inducible transcription factors that regulate many aspects of cell biology and physiology. More recently, their impact on cellular metabolism has been rediscovered. Our understanding of cell-type-specific GC actions and the crosstalk between various immune and stromal cells in arthritis models has evolved by investigating conditional GR mutant mice using the Cre/LoxP system. A major achievement in studying the complex, cell-type-specific interplay is the recent advent of omics technologies at single-cell resolution, which will provide further unprecedented insights into the cell types and factors mediating GC responses. Alongside gene-encoded factors, anti-inflammatory metabolites that participate in resolving inflammation by GCs during arthritis are just being uncovered. The translation of this knowledge into therapeutic concepts will help tackle inflammatory diseases and reduce side effects. In this review, we describe major milestones in preclinical research that led to our current understanding of GC and GR action 75 years after the first use of GCs in arthritis.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1603-1613"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. EULAR/PReS 关于斯蒂尔病(包括全身性幼年特发性关节炎和成人型斯蒂尔病)诊断和管理的建议。
IF 20.3 1区 医学
Annals of the Rheumatic Diseases Pub Date : 2024-11-14 DOI: 10.1136/ard-2024-225851
Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, Sara Bindoli, Jordi Antón, Alexandre Belot, Claudia Bracaglia, Tamàs Constantin, Lorenzo Dagna, Alessandro Di Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei A Grom, Yvan Jamilloux, Katerina Laskari, Calin Lazar, Francesca Minoia, Peter A Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Sebastiaan J Vastert, Tanita-Christina Wilhelmer, Carine Wouters, Loreto Carmona, Fabrizio De Benedetti
{"title":"EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease.","authors":"Bruno Fautrel, Stéphane Mitrovic, Arianna De Matteis, Sara Bindoli, Jordi Antón, Alexandre Belot, Claudia Bracaglia, Tamàs Constantin, Lorenzo Dagna, Alessandro Di Bartolo, Eugen Feist, Dirk Foell, Marco Gattorno, Sophie Georgin-Lavialle, Roberto Giacomelli, Alexei A Grom, Yvan Jamilloux, Katerina Laskari, Calin Lazar, Francesca Minoia, Peter A Nigrovic, Filipa Oliveira Ramos, Seza Ozen, Pierre Quartier, Piero Ruscitti, Erdal Sag, Sinisa Savic, Marie-Elise Truchetet, Sebastiaan J Vastert, Tanita-Christina Wilhelmer, Carine Wouters, Loreto Carmona, Fabrizio De Benedetti","doi":"10.1136/ard-2024-225851","DOIUrl":"10.1136/ard-2024-225851","url":null,"abstract":"<p><p>Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) are considered the same disease, but a common approach for diagnosis and management is still missing.</p><p><strong>Methods: </strong>In May 2022, EULAR and PReS endorsed a proposal for a joint task force (TF) to develop recommendations for the diagnosis and management of sJIA and AOSD. The TF agreed during a first meeting to address four topics: similarity between sJIA and AOSD, diagnostic biomarkers, therapeutic targets and strategies and complications including macrophage activation syndrome (MAS). Systematic literature reviews were conducted accordingly.</p><p><strong>Results: </strong>The TF based their recommendations on four overarching principles, highlighting notably that sJIA and AOSD are one disease, to be designated by one name, Still's disease.Fourteen specific recommendations were issued. Two therapeutic targets were defined: clinically inactive disease (CID) and remission, that is, CID maintained for at least 6 months. The optimal therapeutic strategy relies on early use of interleukin (IL-1 or IL-6 inhibitors associated to short duration glucocorticoid (GC). MAS treatment should rely on high-dose GCs, IL-1 inhibitors, ciclosporin and interferon-γ inhibitors. A specific concern rose recently with cases of severe lung disease in children with Still's disease, for which T cell directed immunosuppressant are suggested. The recommendations emphasised the key role of expert centres for difficult-to-treat patients. All overarching principles and recommendations were agreed by over 80% of the TF experts with a high level of agreement.</p><p><strong>Conclusion: </strong>These recommendations are the first consensus for the diagnosis and management of children and adults with Still's disease.</p>","PeriodicalId":8087,"journal":{"name":"Annals of the Rheumatic Diseases","volume":" ","pages":"1614-1627"},"PeriodicalIF":20.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11672000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信